Benefits of Hemodialysis Plus Hemoperfusion: A Clinical Study
End Stage Renal Disease
About this trial
This is an interventional treatment trial for End Stage Renal Disease
Eligibility Criteria
Inclusion Criteria: Age 18-80 years, regardless of gender Stable maintenance hemodialysis for ≥ 3 months with relatively fixed dialysis pattern Hemodialysis treatment 3 times per week, total treatment duration ≥ 10 hours per week, vascular access unlimited Blood β2-MG > 30 mg/L and/or 300 pg/ml < immunoreactive parathyroid hormone (iPTH) < 800 pg/ml and/or CRP ≥ 16.2 pg/ml Kt/V ≥ 1.2 eight weeks prior to enrollment Signed informed consent form Exclusion Criteria: Known allergic reaction, contraindication or intolerance to the material of the dialyzer or perfusion apparatus Test indicators meeting one or more of the following: white blood cell <4 x 10^9/L, platelet count <60 x 10^9/L, serum albumin <30 g/L Blood flow <200 ml/min Regular hemoperfusion treatment for more than 3 months and at least once every 2 weeks Active bleeding or chronic gastrointestinal bleeding, or other severe bleeding tendencies or coagulation disorders History of unstable angina pectoris, myocardial infarction, severe arrhythmia, pericarditis, myocarditis, cardiac surgery or peripheral vascular surgery in the last 8 weeks Cerebral hemorrhage in the last 12 weeks Severe heart failure (New York Heart Association class IV) Acute infection, acute or critical illnesses such as severe cardiac, pulmonary, hepatic or neurological disease and malignancy Pregnancy or breastfeeding Participation in a clinical trial or ongoing clinical trial within 3 months Expected survival of less than 1 year Not considered suitable for participation in this trial by the investigator
Sites / Locations
- Changhai HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
regular hemodialysis
hemoperfusion combined with hemodialysis
Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
Routine blood purification therapy 3 times a week + Combination of hemodialysis and hemoperfusion treatment once a week